Related Experiment Video
Updated: Sep 22, 2026
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
External Validation and Bayesian Forecasting of Rivaroxaban Population Pharmacokinetic Models in Older Chinese
Jiale Chen1, Weikun Huang2, Guoquan Chen1
1Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People's Republic of China.
Background:
Population pharmacokinetic (PopPK) models have been developed to characterize rivaroxaban exposure; however, their transferability across different clinical populations remains uncertain. This study aimed to externally evaluate published rivaroxaban PopPK models in older Chinese patients with nonvalvular atrial fibrillation (NVAF) and assess whether Bayesian forecasting could improve individual concentration prediction.
Methods:
Six published rivaroxaban PopPK models were evaluated using an independent cohort from the RIVA-GAP study. Predictive performance was assessed using prediction error metrics reflecting bias, precision, and prediction coverage, together with normalized prediction distribution error (NPDE) diagnostics. Bayesian forecasting was performed using paired steady-state trough-peak concentrations to evaluate changes in individual peak concentration prediction.
Results:
A total of 135 patients with 257 rivaroxaban concentration observations were included for external validation, and 122 patients with paired trough-peak samples were included for Bayesian forecasting. Predictive performance varied substantially among the six models, and none consistently met predefined acceptance criteria. Model A showed comparatively lower prediction bias among the evaluated models but still demonstrated limited precision (MDPE 33.64%, MDAPE 53.72%, F30 31.52%). Bayesian forecasting reduced the MDIPE of Model A from 33.64% to 12.38%, but MAIPE remained 37.33% and IF30 was 41.8%. Similar model-dependent effects were observed across the other models.
Conclusion:
Published rivaroxaban PopPK models demonstrated heterogeneous transferability in older Chinese patients with NVAF. Bayesian forecasting using a single trough concentration provided modest and model-dependent improvement in concentration prediction but did not consistently overcome limitations of the underlying models.
Clinical Trial/Study Registration:
Chinese Clinical Trial Registry, ChiCTR2300074934; registered 21 August 2023.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion